Open AccessWhat We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy
Author(s) -
Patricia Zondervan,
Axel Bex
Publication year - 2022
Publication title -
kidney cancer
Language(s) - English
Resource type - Journals
eISSN - 2468-4570
pISSN - 2468-4562
DOI - 10.3233/kca-220004
Subject(s) - renal cell carcinoma , medicine , nephrectomy , clinical trial , oncology , targeted therapy , systemic therapy , nivolumab , immunotherapy , kidney , cancer , breast cancer